Effective dose to immune cells combined with platelet-to-lymphocyte ratio predicts lymphopenia and prognosis in unresectable locally advanced non-small cell lung cancer
In the immunotherapy era, the combination of EDIC and pre-RT PLR is a predictive biomarker of RIL3+ and prognosis in patients with unresectable LA-NSCLC. Reducing EDIC and considering pre-RT PLR may potentially avoid RIL3+ and improve prognosis.
Authors
- Ying Xu (ORCID: https://orcid.org/0000-0002-8941-7560)
- Dawei Chen (ORCID: https://orcid.org/0000-0002-6762-7997)
- Hongbin Yang (ORCID: https://orcid.org/0000-0001-8574-1542)
- Chen Tian (ORCID: https://orcid.org/0000-0003-2710-7628)
- Jinming Yu
- Jingxin Zhang (ORCID: https://orcid.org/0000-0001-7902-1880)
- Jiachun Ma
- Shunshun Bao
- Fei Wang (ORCID: https://orcid.org/0000-0001-9459-9461)
Institutions
- Shandong Tumor Hospital (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-09-24
- DOI
- https://doi.org/10.3389/fimmu.2025.1657972
- Citations
- 1
- Primary Topic
- Inflammatory Biomarkers in Disease Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province